Want to find your lens? Five questions, no jargon — they tell you which of four reads fits how you already think.
We can't give an honest read on this one right now.
Our model values a company on the cash it can hand its owners after paying for its own growth. For Cardinal Health that number is not something we can compute today — so rather than estimate around the gap, we are leaving it blank until the next filings close it.
Why not
- Caution: What is missingCardinal Health closed a run of specialty-care acquisitions in 2025 — GI Alliance for about $2.8B, plus Advanced Diabetes Supply and Integrated Oncology Network — and only its most recent annual year carries any of them. Because those businesses earn very differently from Cardinal's pharmaceutical distribution, they shift the operating-profit and invested-capital mix the read is built on more than the revenue line shows. A five-year base that reflects them is several filings out.
Why show the page at all. Because the alternative is a number we don't believe. Every other company on TickerMath gets a fair value computed from its SEC filings; this one gets a plain explanation instead, which is the same promise kept a different way. This one is expected to change: we re-test every company against its new filings, and the read appears here as soon as the figures support it.
TickerMath is an educational tool, not investment advice — it computes one model from SEC filings and can be wrong. How we compute this →